IBN SINA Pharmaceutical Industry Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares IBN SINA Pharmaceutical Industry Ltd with three other
pharmaceutical manufacturers in Asia:
Panacea Biotec Ltd
sales of 5.39 billion Indian Rupees [US$73.00 million]
of which 76%
YSP Southeast Asia Holding Bhd
(297.06 million Malaysian Ringgits [US$70.91 million]
of which 85%
was Manufacturing), and
Dongsung Pharmaceutical Company Limited
based in KOREA (SOUTH)
(87.80 billion Korean Won [US$74.45 million]
of which 91%
was Pharmaceutical Segment).
During the third
quarter of 2021, sales at IBN SINA Pharmaceutical Industry Ltd totalled
1.79 billion Bangladeshi Taka.
an increase of 16.6%
from the 1.54 billion Bangladeshi Taka in sales at the company during the third quarter of 2020.
During the first three quarters of 2021, sales totalled 5.40 billion Bangladeshi Taka, which is
than through the first three
quarters of 2020.
During the previous 15 quarters, sales at IBN SINA Pharmaceutical Industry Ltd have increased compared with the same quarter in the previous year.
IBN SINA Pharmaceutical Industry Ltd reported sales of 6.19 billion Bangladeshi Taka (US$72.75 million)
June of 2020.
increase of 17.6%
versus 2019, when the company's sales were 5.26 billion Bangladeshi Taka.
Sales at IBN SINA Pharmaceutical Industry Ltd have increased during each of the previous five years
(and since 2015, sales have increased a total of 96%).